文献速递关节外科骨质疏松与代谢性骨病

细胞疗法治疗股骨头坏死的角色

The Role of Cell Therapies for the Treatment of Osteonecrosis of the Femoral Head.
PubMed 文献 · J Arthroplasty · 2025-06-10

本文综述了1990至2024年PubMed文献中辅助细胞疗法治疗塌陷前股骨头坏死的证据,共纳入11项研究(6项随机对照试验和5项回顾性综述)。7项研究支持细胞疗法作为髓芯减压的辅助策略在影像学结局、临床症状或全髋关节置换转化方面获益,4项研究未发现临床或影像学差异。结论认为需要进一步开展足够效能的、多中心、盲法随机对照试验。

要点

  • 7项研究支持细胞疗法辅助髓芯减压改善影像学结局、临床症状或降低全髋关节置换转化。
  • 4项研究(1项回顾性综述和3项随机对照试验)未发现髓芯减压联合细胞疗法与单纯髓芯减压在塌陷进展上有临床或影像学差异。
  • 作者认为现有文献看似有前景,但需进一步研究才能确定疗效,需足够效能、多中心、盲法随机对照试验。

核心结论

  • 作者结论认为,需要进一步开展足够效能的、多中心、盲法随机对照试验。
  • 作者指出,许多研究存在其他局限性,包括间充质细胞含量和标准化方面存在较大变异性。
  • 作者认为,尽管当前关于细胞疗法辅助治疗塌陷前股骨头坏死的文献看似有前景,但需进一步研究才能得出其疗效结论。

研究设计与样本

  • 本文为综述,检索PubMed 1990年至2024年所有评估辅助细胞疗法治疗塌陷前股骨头坏死的研究。
  • 共纳入11项研究,包括6项随机对照试验和5项回顾性综述。
  • 排除IV级研究和非人类研究。

主要发现

  • 7项研究支持细胞疗法作为髓芯减压的辅助策略,在影像学结局(即预防股骨头塌陷)、临床症状或全髋关节置换转化方面获益。
  • 4项研究(1项回顾性综述和3项随机对照试验)发现,接受髓芯减压的患者与接受髓芯减压联合细胞疗法辅助策略的患者在塌陷进展方面无临床或影像学差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出,许多研究存在其他局限性,包括间充质细胞含量和标准化方面存在较大变异性。
  • 作者结论认为,需要进一步开展足够效能的、多中心、盲法随机对照试验。
  • 作者认为,尽管当前文献看似有前景,但需进一步研究才能得出其疗效结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteonecrosis of the femoral head (ONFH) can cause pain, diminished function, and eventual articular collapse, disproportionately impacting younger patients. Core decompression (CD) is used to halt or at least delay postcollapse disease in patients who suffer from ONFH, but it can have variable outcomes. Orthobiologics are cellular therapies, growth factors, and biomaterial substances obtained from human cells and tissue that promote biological healing and have recently gained attention in the treatment of osteonecrosis. In this review, the role of orthobiologics in the treatment of osteonecrosis is discussed. METHODS: We reviewed the existing literature regarding orthobiologics in the treatment of precollapse ONFH. A total of 11 studies were included, consisting of six randomized controlled trials and five retrospective reviews. The included literature was obtained through a PubMed query of all studies from 1990 to 2024 that evaluated the role of ancillary cell-based therapies in the treatment of precollapse ONFH. Level IV and non-human studies were not included. RESULTS: There were seven studies that supported the use of orthobiologics as an augmentation strategy to CD in terms of radiographic outcomes (i.e., prevention of femoral head collapse), clinical symptoms, or conversion to total hip arthroplasty. There were four studies (one retrospective review and three randomized controlled trials) that found no clinical or radiographic difference in collapse progression in patients who received CD versus CD along with an orthobiologic augmentation strategy. CONCLUSIONS: In summary, further adequately powered, multicenter, blinded, randomized controlled trials are necessary. In addition, many of the studies had other limitations, including a large variability in mesenchymal cell content and standardization. Although the current literature regarding orthobiologic augmentation in the treatment of precollapse ONFH appears promising, further investigation is necessary to conclude its efficacy.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Chow SK, Rainey JP, Mont MA, et al. The Role of Cell Therapies for the Treatment of Osteonecrosis of the Femoral Head. J Arthroplasty. 2025. PMID: 40505752. doi:10.1016/j.arth.2025.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。